ALXO — ALX ONCOLOGY HOLDINGS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1810182 ·
Last close
$1.00
Market Cap
$138.97M
52W High
$2.66
52W Low
$0.86
ADV30
1,261,609
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -22,946,000 -21,826,000 154,671,000 35,452,000 28,818,000
Jun 2026 0 — -18,271,000 -17,971,000 160,820,000 22,687,000 24,633,000
Mar 2026 0 — -18,966,000 -17,927,000 178,328,000 32,284,000 26,981,000
Dec 2025 0 — -23,021,000 -22,848,000 59,046,000 16,373,000 33,065,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-70,778,000
Investing CF
$-65,888,000
Financing CF
$140,251,000
CapEx
$-172,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.13
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-758,715,000
Inventory
—
Receivables
$1,171,000
ST Investments
$115,542,000
EBIT TTM
$-79,483,000
Pretax Income TTM
$-80,890,000
Interest Exp TTM
$1,407,000
Analysts
5

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -100,846,000 -101,695,000 59,046,000 33,065,000 25,981,000 -84,142,000
Dec 2024 0 -142,467,000 -134,850,000 147,775,000 34,157,000 113,618,000 -121,912,000
Dec 2023 0 -170,278,000 -160,805,000 242,553,000 52,841,000 189,712,000 -130,364,000
Dec 2022 0 -127,436,000 -123,482,000 306,489,000 43,025,000 263,464,000 -89,223,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$4,065,000
NetIncome TTM
$-80,890,000
OpCashFlow TTM
—
Assets (Latest)
$160,820,000
Forward EPS
$-0.54

Peers — same industry

TickerNameMarket CapLastDaily %
SION Sionna Therapeutics, Inc. $138.87M $3.07 —
RNA Atrium Therapeutics, Inc. $139.78M $6.48 —
MENS Jyong Biotech Ltd. $133.62M $1.80 —
ZNTL Zentalis Pharmaceuticals, Inc. $146.42M $1.49 —
MSLE Satellos Bioscience Inc. $131.54M $6.20 —

News headlines (Yahoo Finance, 1h cache)

ALX Oncology's Two Clinical Readouts Offer Potential Upside, UBS Says
2026-11-17 16:26 · Yahoo
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-16 13:00 · Yahoo
ALX Oncology to Present at Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
2026-09-28 12:00 · Yahoo
ALX Oncology to Present at Upcoming Investor Conferences in September
2026-09-02 12:00 · Yahoo
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
2026-08-11 13:40 · Yahoo
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 12:00 · Yahoo
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
2026-06-30 12:00 · Yahoo
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
2026-05-07 12:00 · Yahoo
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
2026-06-01 17:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.